133 related articles for article (PubMed ID: 38888469)
41. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
42. Structural analyses of the PKA RIIβ holoenzyme containing the oncogenic DnaJB1-PKAc fusion protein reveal protomer asymmetry and fusion-induced allosteric perturbations in fibrolamellar hepatocellular carcinoma.
Lu TW; Aoto PC; Weng JH; Nielsen C; Cash JN; Hall J; Zhang P; Simon SM; Cianfrocco MA; Taylor SS
PLoS Biol; 2020 Dec; 18(12):e3001018. PubMed ID: 33370777
[TBL] [Abstract][Full Text] [Related]
43. Fibrolamellar carcinoma: An entity all its own.
O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K
Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087
[TBL] [Abstract][Full Text] [Related]
44. Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver.
Gummadi J; Wang X; Xie C
J Hepatocell Carcinoma; 2023; 10():745-752. PubMed ID: 37215364
[TBL] [Abstract][Full Text] [Related]
45. Fibrolamellar Carcinoma: What Is New and Why It Matters.
Graham RP
Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
[TBL] [Abstract][Full Text] [Related]
46. Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A.
Olivieri C; Walker C; Karamafrooz A; Wang Y; Manu VS; Porcelli F; Blumenthal DK; Thomas DD; Bernlohr DA; Simon SM; Taylor SS; Veglia G
Commun Biol; 2021 Mar; 4(1):321. PubMed ID: 33692454
[TBL] [Abstract][Full Text] [Related]
47. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Simon EP; Freije CA; Farber BA; Lalazar G; Darcy DG; Honeyman JN; Chiaroni-Clarke R; Dill BD; Molina H; Bhanot UK; La Quaglia MP; Rosenberg BR; Simon SM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):E5916-25. PubMed ID: 26489647
[TBL] [Abstract][Full Text] [Related]
48. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Graham RP; Torbenson MS
Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
[TBL] [Abstract][Full Text] [Related]
49. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract][Full Text] [Related]
50. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Reid LM; Sethupathy P
Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
[No Abstract] [Full Text] [Related]
51. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
52. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract][Full Text] [Related]
53. Intracranial metastasis in fibrolamellar hepatocellular carcinoma.
Hammond WJ; Lalazar G; Saltsman JA; Farber BA; Danzer E; Sherpa TC; Banda CD; Andolina JR; Karimi S; Brennan CW; Torbenson MS; La Quaglia MP; Simon SM
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286561
[TBL] [Abstract][Full Text] [Related]
54. PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors.
Berthon AS; Szarek E; Stratakis CA
Front Cell Dev Biol; 2015; 3():26. PubMed ID: 26042218
[TBL] [Abstract][Full Text] [Related]
55. Cyclic AMP-dependent protein kinase catalytic subunit A (PRKACA): the expected, the unexpected, and what might be next.
Stratakis CA
J Pathol; 2018 Mar; 244(3):257-259. PubMed ID: 29205368
[TBL] [Abstract][Full Text] [Related]
56. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
57. Studies of mice with cyclic AMP-dependent protein kinase (PKA) defects reveal the critical role of PKA's catalytic subunits in anxiety.
Briassoulis G; Keil MF; Naved B; Liu S; Starost MF; Nesterova M; Gokarn N; Batistatos A; Wu TJ; Stratakis CA
Behav Brain Res; 2016 Jul; 307():1-10. PubMed ID: 26992826
[TBL] [Abstract][Full Text] [Related]
58. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract][Full Text] [Related]
59. Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα.
Cao B; Lu TW; Martinez Fiesco JA; Tomasini M; Fan L; Simon SM; Taylor SS; Zhang P
Structure; 2019 May; 27(5):816-828.e4. PubMed ID: 30905674
[TBL] [Abstract][Full Text] [Related]
60. Histopathological Spectrum and Molecular Characterization of Liver Tumors in the Setting of Fontan-Associated Liver Disease.
Francalanci P; Giovannoni I; Tancredi C; Gagliardi MG; Palmieri R; Brancaccio G; Spada M; Maggiore G; Pietrobattista A; Monti L; Castellano A; Giustiniani MC; Onetti Muda A; Alaggio R
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
